Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Day One Biopharmaceuticals, Inc. - Common Stock
(NQ:
DAWN
)
9.970
+1.210 (+13.81%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 18, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Day One Biopharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
April 25, 2023
Gainers
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
↗
April 25, 2023
Via
Benzinga
What 5 Analyst Ratings Have To Say About Day One Biopharmaceutical
↗
April 25, 2023
Via
Benzinga
Analyst Expectations for Day One Biopharmaceutical's Future
↗
April 05, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
April 25, 2023
Via
Benzinga
Lam Research, D.R. Horton, Las Vegas Sands And Other Big Stocks Moving Higher On Thursday
↗
April 20, 2023
U.S. stocks traded lower, with the Dow Jones dropping around 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
April 12, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
What 8 Analyst Ratings Have To Say About Day One Biopharmaceutical
↗
March 07, 2023
Via
Benzinga
Where Day One Biopharmaceutical Stands With Analysts
↗
February 03, 2023
Via
Benzinga
What 7 Analyst Ratings Have To Say About Day One Biopharmaceutical
↗
January 09, 2023
Via
Benzinga
This Pediatric Cancer Company Makes It To Analyst's Conviction List
↗
December 14, 2022
Via
Benzinga
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
March 06, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Participate in the Cowen 43rd Annual Health Care Conference
February 27, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
February 16, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
↗
February 03, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023
↗
February 08, 2023
Via
Benzinga
Day One Biopharmaceuticals Shares Jump As Pediatric Brain Cancer Candidate Shows Encouraging Responses
↗
January 09, 2023
Via
Benzinga
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
January 08, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
↗
December 05, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
↗
December 15, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
↗
December 14, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
↗
December 01, 2022
Via
Benzinga
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 17, 2022
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting
November 11, 2022
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Third Quarter 2022 Financial Results and Corporate Progress
November 07, 2022
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)
October 17, 2022
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
October 12, 2022
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide...
Via
FinancialNewsMedia
5 Value Stocks In The Healthcare Sector
↗
August 22, 2022
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators...
Via
Benzinga
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
↗
August 15, 2022
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today